| Status | 已發表Published |
| PHP51 Utilization of monoclonal antibody in China: a study from national market access view | |
Lai, Y. ; Bie, R.; Suo, S.; Shi, H.; Chen, S.; Ung, O. L. C.; Hu, H.
| |
| 2018-12-01 | |
| Source Publication | Value in Health
 |
| Pages | S159-S159 |
| Abstract | OBJECTIVES: Because of its high price, monoclonal antibody (mAb) faces challenges of market access in China. Thus, this study aimed to investigate the utilization of mAb at Grade 2 and Grade 3 hospitals located in three different regions in China, expecting to provide evidence for improving mAb accessibility. METHODS: The CHIS database (2017) was applied in this study, which collected drug procurement data from Grade 2 and Grade 3 hospitals over 30 provinces (municipalities) in China. 18 mAb products (10 imported; 8 domestic) were included. The sales value per hospital was analyzed and compared by hospital levels and regions through ANOVA analysis. RESULTS: In 2017, for the total sample hospitals, the average sales value per hospital was 3,916,459.95 CNY (n ¼ 640). The average sales value per Grade 2 hospital was 694,960.35 CNY (n ¼ 136); the average sales value per Grade 3 hospital was 4,785,753.49 CNY (n ¼ 504); with significant difference (p ¼ 0.001). Regarding region difference among Grade 2 hospitals, the average sales value per Grade 2 hospital was 833,700.97 CNY (eastern, n ¼ 100), 186,035.55 CNY (middle, n ¼ 21), and 482,517.58 CNY (western; n ¼ 15); without statistical significance (p ¼ 0.320). Regarding region difference among Grade 3 hospitals, the average sales value per Grade 3 hospital was 5,534,684.50 CNY (eastern, n ¼ 328), 2,987,429.67 CNY (middle, n ¼ 120), and 4,252,708.62 CNY (western, n ¼ 56); without statistical significance (p ¼ 0.235). CONCLUSIONS: The utilization of mAb in China mainly concentrated in Grade 3 hospitals without significant region differences. Future efforts need to promote mAb access to Grade 2 hospitals. |
| Keyword | mAb market access |
| Language | 英語English |
| The Source to Article | PB_Publication |
| PUB ID | 44058 |
| Document Type | Conference paper |
| Collection | Institute of Chinese Medical Sciences |
| Recommended Citation GB/T 7714 | Lai, Y.,Bie, R.,Suo, S.,et al. PHP51 Utilization of monoclonal antibody in China: a study from national market access view[C], 2018, S159-S159. |
| APA | Lai, Y.., Bie, R.., Suo, S.., Shi, H.., Chen, S.., Ung, O. L. C.., & Hu, H. (2018). PHP51 Utilization of monoclonal antibody in China: a study from national market access view. Value in Health, S159-S159. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment